Posted inBiotechnology
Agios says adios to sickle cell program over lackluster phase 2 data
A phase 2 study of Agios Pharmaceuticals’ next-generation pyruvate kinase activator has failed to support continued development in sickle cell…
Posted inBiotechnology
Novartis drops phase 2 radioligand therapy, but CEO’s commitment to modality ‘unchanged’
Novartis has dropped a phase 2-stage radioligand therapy after the candidate disappointed in the clinic.
Posted inBiotechnology
Indian generics maker Lupin seeds US spinout Kaveri with cash, clinical-phase cancer assets
Lupin has spun out two clinical-phase cancer drug candidates to create Kaveri Therapeutics, a U.S.-based startup that plans to raise…
Posted inMedical Technology
Roche taps Foundation Medicine’s chief as new North America Diagnostics lead, creates new commercial role
Dan Malarek is leaving his role as chief executive of Roche’s sequencing subsidiary Foundation Medicine as he takes up the…
Posted inGenetics
Early Genomic Indicators of Praziquantel Resistance in Schistosoma mansoni
Credit: defun / iStock / Getty Images Plus The warning signs are subtle—genetic variants scattered across a vast parasite genome—but…
Posted inGenetics
Flu Virus Interaction with Host Cell Machinery Mapped Inside Infected Cells
Researchers at EMBL Hamburg and collaborators at the Leibniz Research Institute for Molecular Pharmacology (FMP) have mapped in unprecedented detail…
Posted inGenetics
Protein Protects Against Tau Tangles, Synaptic Loss in Mouse Model of Tauopathy
Credit: Juan Gaertner/Science Photo Library/Getty Images Alzheimer’s disease (AD) and many other forms of neurodegeneration share a common culprit. In…
Posted inGenetics
Patient-Derived Tumor Organoids Show Promise for Personalizing Cancer Treatment
Immunofluorescent image of colorectal cancer organoids. The nuclei are stained blue, along with staining for γ-H2AX (red), which shows where…
Posted inGenetics
Memory Shaped by Brain Remodeling During Adolescence in Mice
Credit: Viaframe/Getty Images The human brain continues developing beyond the teenage years, with crucial changes involving decision-making and emotional regulation…
Posted inBiotechnology
‘There is always a first’: Why US biotech Axiom will begin its IPO journey in Hong Kong
Axiom Biosciences intends to pursue an IPO on the Hong Kong Stock Exchange (HKEX) followed by a co-listing on the…